IDH1 and central nervous system cancer: Mutations of IDH1 and IDH2 have been recognized as oncogenic events through decreasing α-ketoglutarate and increasing D-2-hydroxyglutarate production (20), and the neomorphic IDH mutant has been shown in acute myeloid leukemia (21) and gliomas (22).